12 April 2019 - Following their Senate Finance Committee hearing in February, all seven biopharmaceutical CEOs have now offered hundreds of pages of written responses to more specific questions.

The lackluster biosimilar market in the US is addressed in nearly all their comments, with some executives explaining in detail as to why their biosimilars have yet to gain market share, while undertones of biosimilar fear-mongering linger in others’ comments.

Merck CEO Kenneth Frazier explained to Senator Mike Enzi how in general, biosimilar competition in the US “thus far has resulted in moderation of prices, but actual utilization of the biosimilars remains modest at best. We fear that an environment where market entry of biosimilars brings value to the market, but little or none of that value accrues to the biosimilar patient or the health care system, will not be sustainable.”

Read Regulatory Affairs Professional Society article